CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma, has secured marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) for its bevacizumab biosimilar, Bevqolva®. The approval, granted under Form CT 23, allows the manufacture and marketing of Bevqolva® for the treatment of metastatic carcinoma of the colon or rectum.
The authorisation permits the production of Bevqolva® at CuraTeQ’s facility located in Hyderabad. The biosimilar will be available in two vial presentations: 100 mg/4mL and 400 mg/16 mL. This development marks a significant milestone for CuraTeQ Biologics in expanding its oncology product portfolio.
Bevacizumab, the active ingredient in Bevqolva®, is a monoclonal antibody that inhibits angiogenesis, a process critical to the growth of cancerous tumours. By receiving this marketing authorisation, CuraTeQ Biologics is poised to enhance its presence in the oncology biosimilars market, offering a cost-effective alternative to existing therapies.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).